← Leaderboard
BIIB
Ticker
BIIB
Biogen Inc.
Healthcare
Congressional Trades
32
by 6 members
Ticker Intelligence Brief
Who in Congress traded BIIB, when, and what happened after?
A ticker-first view for retail/data users: latest disclosure, largest range, disclosure lag, party flow, contracts, lobbying, and source-linked receipts.
Latest receipt
Maria Salazar
BUY · 2026-05-12
Largest range
$50K – $100K
Maria Salazar
Slowest filing
35d
Ro Khanna
Best vs SPY
33.2%
Robert Bresnahan
Buys
20
63%
Sells
12
38%
Total Volume
$415K
midpoint
Unique Traders
6
members
Party Breakdown
Democrats22 · 69%
Republicans10 · 31%
Party Trading Divergence
Democrat vs. Republican buy / sell pressure by monthHIGH DIVERGENCEBar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.
Democrat ←
Month
→ Republican
0▲1▼
Jan '23
—
0▲2▼
Mar '24
—
1▲
Apr '24
—
1▲1▼
Aug '24
—
1▲
Oct '24
—
1▲
Nov '24
—
0▲1▼
Jan '25
—
1▲1▼
Feb '25
1▲
1▲
Apr '25⚡
0▲1▼
0▲1▼
May '25⚡
2▲
1▲
Aug '25
—
3▲
Jan '26
—
0▲1▼
Feb '26
—
0▲1▼
Apr '26
—
1▲1▼
May '26
6▲
Democrats11▲10▼Neutral
vs
Republicans9▲1▼Net buyers
Net buyingNet selling⚡ Party split
💼 Lobbying Filings
all →- 2026-04-20$1.5MBIOGENDiscussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill. Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Al
- 2026-04-20$60KBIOGEN INC.Issues related to tax reform. Trade-related public policy around tariffs and intellectual property. Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D. Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. Intellectual property protections and enforcement. Biopharmaceutical pat
- 2026-04-20$50KBIOGEN INC.Issues related to Medicare Part B and Part D Issues related to the pharmaceutical industry
- 2026-04-20$50KBIOGEN INC.Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. 340B Program. PPRV (Pediatric Priority Review Voucher) program. Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. 340B Program.
- 2026-04-20$50KBIOGEN INC.Issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment. Issues related to the budget and appropriations process Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Issues related to the budget and appropriations process
- 2026-03-09$50KBIOGEN INC.Issues related to Medicare Part B and Part D Issues related to the pharmaceutical industry
- 2026-01-20$60KBIOGEN INC.Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D. Issues related to tax reform. Trade-related public policy around tariffs and intellectual property. Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. Intellectual property protections and enforcement. Biopharmaceutical pat
- 2026-01-20$50KBIOGEN INC.Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. 340B Program. PPRV (Pediatric Priority Review Voucher) program. Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. 340B Program.
- 2026-01-20$50KBIOGEN INC.Issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment. Issues related to the FY2026 budget and appropriations process Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Issues related to the FY2026 budget and appropriations process
- 2026-01-19$770KBIOGENDiscussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill. Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income. Trade-related public policy around tariffs and intellectual property, no related bills Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated
Congressional Momentum
buy vs. sell pressureACCUMULATINGScore 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.
Last 30 Days
▼0
0 buys1 total1 sell
$0 buys · $8K sells
Last 90 Days
▲92
7 buys9 total2 sells
$190K buys · $16K sells
All-Time
▲71
20 buys32 total12 sells
$294K buys · $121K sells
Cumulative Net Position (buy vol − sell vol)
+$174K
2019-0332 trades plotted2026-05
Best Timers
avg excess return vs SPY · BIIB trades only4 members w/ alpha dataExcess return = stock price change minus SPY change over the same holding window.Congress avg: +4.6%· 50% of traders beat SPY on this name
Top Alpha Generators
D:2R:2House:4
underperformed SPY|beat SPY
Worst Timers
bottom 4 by avg excess return
underperformed SPY|beat SPY
Worst single trade: Ro Khanna (-49.2%)Best single trade: Robert Bresnahan (+33.2%)
Timing Fingerprint
filing delay vs. excess return over SPY · 28 tradesCongress avg -1.8% vs SPYEach dot = one disclosed trade. X-axis = days between trade and STOCK Act filing.Y-axis = return above (or below) SPY over the subsequent holding window. Upper-right = late filers who beat the market.
57% of trades beat SPYavg excess -1.8%avg delay 22d18 buys10 sellsBuySellOther· dot size ∝ trade size
Trade Activity Timeline
Congressional buys & sells by month · last 16 months w/ activity
19/03
23/01
24/03
24/04
24/08
24/10
24/11
25/01
25/02
25/04
25/05
25/08
26/01
26/02
26/04
26/05
BuysSellsOtherHigh-volume month
Who Moved First
each row = one member · sorted by earliest disclosed trade4 buyers ·4 sellers
BuySellOtherDot size ∝ trade size · top 6 most-active traders shown
Seasonal Rhythm
Congress buy/sell pressure by month & yearEach cell = one calendar month. Green = net Congress buying, red = net selling. Intensity ∝ consensus strength. Hover for details.
Net buyingNet sellingNo trades · number = trade count
Peak buy month: May · Peak sell month: Mar
Congressional Conviction Timeline
net positioning · alpha track recordBULLISH20 buys12 sellscumulative α +2.0%16mo tracked
Monthly Net Flow (Buys − Sells)
Cumulative Excess Return on Congressional Buys vs SPY
All Disclosed Trades
| Date | Member | Action | Amount | Filing Delay | Receipt |
|---|---|---|---|---|---|
| 2026-05-12 | RMaria Salazar | BUY | $1K – $15K | 28d | receipt → |
| 2026-05-11 | RMaria Salazar | BUY | $50K – $100K | 29d | receipt → |
| 2026-05-11 | RMaria Salazar | BUY | $1K – $15K | 29d | receipt → |
| 2026-05-27 | DRo Khanna | SELL | $1K – $15K | 13d | receipt → |
| 2026-05-15 | DRo Khanna | BUY | $1K – $15K | 25d | receipt → |
| 2026-05-12 | RMaria Salazar | BUY | $1K – $15K | 27d | receipt → |
| 2026-05-11 | RMaria Salazar | BUY | $50K – $100K | 28d | receipt → |
| 2026-05-11 | RMaria Salazar | BUY | $1K – $15K | 28d | receipt → |
| 2026-04-13 | DRo Khanna | SELL | $1K – $15K | 28d | receipt → |
| 2026-02-06 | DRo Khanna | SELL | $1K – $15K | 31d | receipt → |
| 2026-01-30 | DGilbert Cisneros | BUY | $1K – $15K | 17d | receipt → |
| 2026-01-30 | DGilbert Cisneros | BUY | $1K – $15K | 14d | receipt → |
| 2026-01-29 | DRo Khanna | BUY | $1K – $15K | 8d | receipt → |
| 2025-08-26 | DRo Khanna | BUY | $1K – $15K | 14d | receipt → |
| 2025-05-15 | RRobert Bresnahan | BUY | $1K – $15K | 26d | receipt → |
| 2025-05-19 | DRo Khanna | SELL | $1K – $15K | 22d | receipt → |
| 2025-05-15 | RRobert Bresnahan | BUY | $1K – $15K | 25d | receipt → |
| 2025-04-23 | DRo Khanna | BUY | $1K – $15K | 19d | receipt → |
| 2025-04-08 | RRobert Bresnahan | SELL | $1K – $15K | 30d | receipt → |
| 2025-02-25 | RRobert Bresnahan | BUY | $1K – $15K | 30d | receipt → |
| 2025-02-25 | DRo Khanna | BUY | $1K – $15K | 9d | receipt → |
| 2025-02-19 | DRo Khanna | SELL | $1K – $15K | 15d | receipt → |
| 2025-01-17 | DRo Khanna | SELL | $1K – $15K | 20d | receipt → |
| 2024-11-15 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2024-10-14 | DRo Khanna | BUY | $1K – $15K | 25d | receipt → |
| 2024-08-05 | DRo Khanna | SELL | $1K – $15K | 32d | receipt → |
| 2024-08-02 | DRo Khanna | BUY | $1K – $15K | 35d | receipt → |
| 2024-04-26 | DRo Khanna | BUY | $1K – $15K | 10d | receipt → |
| 2024-03-25 | DRo Khanna | SELL | $1K – $15K | 11d | receipt → |
| 2024-03-20 | DRo Khanna | SELL | $1K – $15K | 16d | receipt → |
| 2019-03-22 | DSheldon Whitehouse | SELL | $1K – $15K | 1620d | receipt → |
| 2023-01-23 | DShri Thanedar | SELL | $15K – $50K | 7d | receipt → |